Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00605735 | PoC in Rheumatoid Arthritis With Methotrexate | PHASE2 | COMPLETED | 121 | — | — | Mar 1, 2008 | Sep 1, 2009 | Oct 12, 2015 | 28 | United States, Argentina +6 |
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| P1 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-582949 | DRUG | Tablets, Oral, 300 mg, once daily, 12 weeks |
| Placebo | DRUG | Tablets, Oral, placebo, once daily, 12 weeks |
Inclusion Criteria: * Must have a diagnosis of RA for at least 6 months * Must be taking methotrexate for at least 3 months \& on a stable dose of 7.5-30 mg weekly) for 4 weeks before dosing with study medication * Must have at least 6 swollen and at least 8 tender joints * CRP above upper limit of...